Literature DB >> 21277109

Preclinical assessment of volumetric modulated arc therapy for total marrow irradiation.

Antonella Fogliata1, Luca Cozzi, Alessandro Clivio, Adalberto Ibatici, Pietro Mancosu, Piera Navarria, Giorgia Nicolini, Armando Santoro, Eugenio Vanetti, Marta Scorsetti.   

Abstract

PURPOSE: A preclinical investigation was undertaken to explore a treatment technique for total marrow irradiation using RapidArc, a volumetric modulated arc technique.
MATERIALS AND METHODS: Computed tomography datasets of 5 patients were included. Plans with eight overlapping coaxial arcs were optimized for 6-MV photon beams. Dose prescription was 12 Gy in 2 Gy per fraction, normalized so that 100% isodose covered 85% of the planning target volume (PTV). The PTV consisted of the whole skeleton (including ribs and sternum), from the top of the skull to the medium distal third of the femurs. Planning objectives for organs at risk (OARs) were constrained to a median dose <6 to 7 Gy. OARs included brain, eyes, oral cavity, parotids, thyroid, lungs, heart, kidneys, liver, spleen, stomach, abdominal cavity, bladder, rectum, and genitals. Pretreatment quality assurance consisted of portal dosimetry comparisons, scoring the delivery to calculation agreement with the gamma agreement index.
RESULTS: The median total body volume in the study was 57 liters (range, 49-81 liters), for an average diameter of 47 cm (range, 46-53 cm) and a total length ranging from 95 to 112 cm. The median PTV volume was 6.8 liters (range, 5.8-10.8 liters). The mean dose to PTV was 109% (range, 107-112%). The global mean of median dose to all OARs was 4.9 Gy (range, 4.5-5.1 Gy over the 5 patients). The individual mean of median doses per organ ranged from 2.3 Gy (oral cavity) to 7.3 Gy (bowels cavity). Preclinical quality assurance resulted in a mean gamma agreement index of 94.3 ± 5.1%. The delivery time measured from quality assurance runs was 13 minutes.
CONCLUSION: Sparing of normal tissues with adequate coverage of skeletal bones was shown to be feasible with RapidArc. Pretreatment quality assurance measurements confirmed the technical agreement between expected and actually delivered dose distributions, suggesting the possibility of incorporating this technique in the treatment options for patients.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21277109     DOI: 10.1016/j.ijrobp.2010.11.028

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  23 in total

Review 1.  Volumetric modulated arc therapy: a review of current literature and clinical use in practice.

Authors:  M Teoh; C H Clark; K Wood; S Whitaker; A Nisbet
Journal:  Br J Radiol       Date:  2011-11       Impact factor: 3.039

2.  A dosimetric analysis of volumetric-modulated arc radiotherapy with jaw width restriction vs 7 field intensity-modulated radiotherapy for definitive treatment of cervical cancer.

Authors:  B Huang; Z Fang; Y Huang; P Lin; Z Chen
Journal:  Br J Radiol       Date:  2014-05-16       Impact factor: 3.039

3.  Performance of the eclipse monitor unit objective tool utilizing volumetric modulated arc therapy for rectal cancer.

Authors:  Alejandro Prado; Ángel Gaitán; Mario Leonor; Marta Manzano; Eduardo Cabello; Raúl Díaz; Alejandro Ferrando; Ana Milanés; Gustavo Pozo
Journal:  Rep Pract Oncol Radiother       Date:  2019-02-25

4.  Stereotactic body radiation therapy for liver tumours using flattening filter free beam: dosimetric and technical considerations.

Authors:  Pietro Mancosu; Simona Castiglioni; Giacomo Reggiori; Maddalena Catalano; Filippo Alongi; Chiara Pellegrini; Stefano Arcangeli; Angelo Tozzi; Francesca Lobefalo; Antonella Fogliata; Piera Navarria; Luca Cozzi; Marta Scorsetti
Journal:  Radiat Oncol       Date:  2012-02-01       Impact factor: 3.481

5.  In-vivo dosimetry with Gafchromic films for multi-isocentric VMAT irradiation of total marrow lymph-nodes: a feasibility study.

Authors:  Pietro Mancosu; Pierina Navarria; Giacomo Reggiori; Luca Cozzi; Antonella Fogliata; Anna Gaudino; Francesca Lobefalo; Lucia Paganini; Valentina Palumbo; Barbara Sarina; Antonella Stravato; Luca Castagna; Stefano Tomatis; Marta Scorsetti
Journal:  Radiat Oncol       Date:  2015-04-12       Impact factor: 3.481

6.  Verification of junction dose between VMAT arcs of total body irradiation using a Sun Nuclear ArcCHECK phantom.

Authors:  Colm T Morrison; Kirsty L Symons; Simon J Woodings; Michael J House
Journal:  J Appl Clin Med Phys       Date:  2017-10-29       Impact factor: 2.102

7.  First Multimodal, Three-Dimensional, Image-Guided Total Marrow Irradiation Model for Preclinical Bone Marrow Transplantation Studies.

Authors:  Darren Zuro; Srideshikan Sargur Madabushi; Jamison Brooks; Bihong T Chen; Janagama Goud; Amandeep Salhotra; Joo Y Song; Liliana Echavarria Parra; Antonio Pierini; James F Sanchez; Anthony Stein; Monzr Al Malki; Marcin Kortylewski; Jeffrey Y C Wong; Parham Alaei; Jerry Froelich; Guy Storme; Susanta K Hui
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-06-11       Impact factor: 7.038

8.  Fast, simple, and informative patient-specific dose verification method for intensity modulated total marrow irradiation with helical tomotherapy.

Authors:  Yutaka Takahashi; Susanta K Hui
Journal:  Radiat Oncol       Date:  2014-01-25       Impact factor: 3.481

9.  Total body irradiation with volumetric modulated arc therapy: Dosimetric data and first clinical experience.

Authors:  Andreas Springer; Josef Hammer; Erwin Winkler; Christine Track; Roswitha Huppert; Alexandra Böhm; Hedwig Kasparu; Ansgar Weltermann; Gregor Aschauer; Andreas L Petzer; Ernst Putz; Alexander Altenburger; Rainer Gruber; Karin Moser; Karin Wiesauer; Hans Geinitz
Journal:  Radiat Oncol       Date:  2016-03-22       Impact factor: 3.481

10.  Feasibility study on dosimetry verification of volumetric-modulated arc therapy-based total marrow irradiation.

Authors:  Yun Liang; Gwe-Ya Kim; Todd Pawlicki; Arno J Mundt; Loren K Mell
Journal:  J Appl Clin Med Phys       Date:  2013-03-04       Impact factor: 2.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.